New hope for scleroderma: drug trial targets skin hardening
Disease control
Recruiting now
This study tests a drug called nemolizumab in 162 adults with systemic sclerosis, a disease that causes skin thickening and organ problems. The goal is to see if it safely reduces skin hardness over 52 weeks and to find the best dose. Participants are randomly assigned to receive…
Phase: PHASE2 • Sponsor: Galderma R&D • Aim: Disease control
Last updated Apr 26, 2026 19:38 UTC